In a nutshell
This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant.
High-risk lymphoma patients with relapsing or unresponsive (refractory) disease may be candidates for allogeneic stem cell transplantation (SCT). This procedure requires a close tissue type match between the donor and the patient, such as a sibling.
70% of patients don’t have an exact tissue type match. For these patients, haploidentical transplantation can achieve a 50% match. This makes it easier to find donors, helping treat patients more quickly. Stem cells from umbilical cord blood can also be used, but these cells take a long time to restore white blood cell counts. This increases hospitalization time and care costs. Combining these methods could provide the best of both: faster white blood cell recovery with a lower risk of graft-versus-host disease (GVHD, when the transplanted cells attack healthy tissue).
Methods & findings
This study involved 42 patients with a range of lymphomas, both non-Hodgkin’s or Hodgkin’s, or CLL. 29% of patients were in complete remission, while 71% had active disease. 57% of patients were at high or very high risk. 52% of patients had received three or more lines of therapy prior to the transplant procedure.
By 60 days post-transplant, 100% of patients had white blood cell recovery, and 91% of patients had platelet (blood cells involved in clotting) count recovery. 21% of patients developed acute GHVD, with an 8% occurrence of chronic GHVD at 1 year. 28% of patients experienced disease progression or relapse, with a 19.5% occurrence of relapse at 1 year. Overall, CLL and follicular lymphoma (FL) patients had the best outcomes, staying in remission.
At an average follow-up of 42 months, the rate of relapse-free survival (time from treatment until disease return) was 53%. Progression-free survival (time from treatment until disease progression) was 62%, and overall survival (time from treatment until death from any cause) was 65%.
Epstein-Barr virus (EBV) reactivation occurred in 31%. Cytomegalovirus (CMV) reactivation occurred in 36%. Both were easily controlled with treatment.
The bottom line
This study concluded that combined haploidentical cord transplant provides fast white blood cell recovery and low rates of GVHD, making it a good alternative treatment for patients with high-risk, relapsed, or refractory lymphomas.
The fine print
This study only had 42 patients, which is a very small sample size. T-cell and Hodgkin’s lymphoma represented the two largest groups of patients (31% and 21%), but more studies with larger patient populations are needed for comparison.
If you have relapsed or refractory lymphoma, talk to your care team about a combined haploidentical cord transplant as an alternative treatment option.
Published By :
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Nov 08, 2017
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?